255 related articles for article (PubMed ID: 34374613)
1. Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia.
Ceppi F; Rizzati F; Colombini A; Conter V; Cazzaniga G
Expert Rev Hematol; 2021 Sep; 14(9):795-807. PubMed ID: 34374613
[TBL] [Abstract][Full Text] [Related]
2. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
4. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
Chen X; Wood BL
Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
[TBL] [Abstract][Full Text] [Related]
5. Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
Algamal RA; Abu Samra NK; Ellashery RA; Abd-EL-Hameed SAE; Shahin DA
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3577-3584. PubMed ID: 37898866
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia.
Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Martínez Banaclocha H; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A
Clin Transl Oncol; 2024 Jan; 26(1):278-287. PubMed ID: 37368200
[TBL] [Abstract][Full Text] [Related]
8. Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia.
Qin X; Zhang MY; Liu WJ
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6885-6895. PubMed ID: 30402854
[TBL] [Abstract][Full Text] [Related]
9. How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?
Chen X; Wood BL
Best Pract Res Clin Haematol; 2017 Sep; 30(3):237-248. PubMed ID: 29050697
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
11. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.
Campana D
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1083-98, vii. PubMed ID: 19825454
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
[TBL] [Abstract][Full Text] [Related]
13. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction.
Cheng SH; Lau KM; Li CK; Chan NP; Ip RK; Cheng CK; Lee V; Shing MM; Leung AW; Ha SY; Cheuk DK; Lee AC; Li CH; Luk CW; Ling SC; Hrusak O; Mejstrikova E; Leung Y; Ng MH
PLoS One; 2013; 8(7):e69467. PubMed ID: 23936021
[TBL] [Abstract][Full Text] [Related]
16. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
Verbeek MWC; van der Velden VHJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
[TBL] [Abstract][Full Text] [Related]
17. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
Front Oncol; 2019; 9():726. PubMed ID: 31448230
[No Abstract] [Full Text] [Related]
18. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
Campana D
Curr Opin Hematol; 2012 Jul; 19(4):313-8. PubMed ID: 22525580
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia.
Hrabovsky S; Folber F; Horacek JM; Stehlikova O; Jelinkova H; Salek C; Doubek M;
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):743-748. PubMed ID: 30057330
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
